Sponsor content
18 result(s) found, displaying 11 to 18
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XEMBIFY normal immunoglobulin 2 g/10 mL (20%) solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XEMBIFY normal immunoglobulin 1 g/5 mL (20%) solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PROLASTIN C LIQUID alpha-1-proteinase inhibitor (human) 500 mg solution for injection for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PROLASTIN C LIQUID alpha-1-proteinase inhibitor (human) 4000 mg solution for injection for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Grifols Australia Pty Ltd - Immunohaematology blood grouping antisera IVDs.
-
Prescription medicine decision summaryTGA decision: Xembify (normal immunoglobulin human) is approved to treat primary immunodeficiency diseases (PID).
-
Australian public assessment report (AusPar)VeraSeal (human fibrinogen and human thrombin) for the supportive treatment of hemostasis.
-
Prescription medicine registrationActive ingredients: human immunoglobulin G.